Details of the Drug-Related molecule(s) Interaction Atlas

General Information of DTT (ID: TTUTJGQ)

• DTT Name: Vascular endothelial growth factor receptor 2 (KDR) DTT Info
• Gene Name: KDR

Molecule-Related Drug & Molecule List

13 Approved Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Axitinib	DMGVH6N	Renal cell carcinoma	2C90	Approved	[1]
Cabozantinib	DMIYDT4	Medullary thyroid gland carcinoma		Approved	[2]
Fruquintinib	DMHOSCQ	Colorectal cancer	2B91.Z	Approved	[3]
Lenvatinib	DMB1IU4	Thyroid cancer	2D10	Approved	[4]
Pazopanib HCl	DM6U9CQ	Renal cell carcinoma	2C90	Approved	[5]
Ramucirumab	DMWUFQ4	Gastric adenocarcinoma	2B72	Approved	[6]
Regorafenib	DMHSY1I	Gastrointestinal stromal tumour	2B5B	Approved	[7]
Romiplostim	DM3U7SZ	Thrombocytopenia	3B64	Approved	[8]
Sorafenib	DMS8IFC	Adenocarcinoma	2D40	Approved	[9]
Sunitinib	DMCBJSR	Acute undifferentiated leukemia		Approved	[10]
Tivozanib	DMUKC5L	Renal cell carcinoma	2C90	Approved	[11]
Vandetanib	DMRICNP	Solid tumour/cancer	2A00-2F9Z	Approved	[12]
YN-968D1	DMMP3Y2	Breast cancer	2C60-2C65	Approved	[13]

34 Clinical Trial Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Brivanib	DM942HP	Breast cancer	2C60-2C65	Phase 3	[14]
Cediranib	DMWO5ZR	Peritoneal cavity cancer	2C51.Z	Phase 3	[12]
E-3810	DM42PFT	Solid tumour/cancer	2A00-2F9Z	Phase 3	[15]
HKI-272	DM6QOVN	Breast cancer	2C60-2C65	Phase 3	[16]
Rivoceranib	DM13V0P	Gastric adenocarcinoma	2B72	Phase 3	[17]
Sulfatinib	DMPOTM4	Neuroendocrine cancer	2B72.1	Phase 3	[18]
MGCD516	DM752PU	Solid tumour/cancer	2A00-2F9Z	Phase 2/3	[19]
Alacizumab pegol	DM3P91Z	Non-small-cell lung cancer	2C25.Y	Phase 2	[20]
BAY-57-9352	DMVA5NS	Gastric adenocarcinoma	2B72	Phase 2	[12]
BMS-690514	DMX302C	Chronic pain	MG30	Phase 2	[21]
CP-547632	DMX054A	Non-small-cell lung cancer	2C25.Y	Phase 2	[12]
Delphinidin	DMS2WIN	Cardiovascular disease	BA00-BE2Z	Phase 2	[22]
Famitinib	DMSFWT7	Solid tumour/cancer	2A00-2F9Z	Phase 2	[23]
L-DOS47	DMIEZUB	Non-small-cell lung cancer	2C25.Y	Phase 2	[24]
RAF265	DMC56T4	Melanoma	2C30	Phase 2	[25]
TTAC-0001	DM6TAFE	Recurrent glioblastoma	2A00.00	Phase 2	[19]
VATALANIB	DMY0UEQ	Solid tumour/cancer	2A00-2F9Z	Phase 2	[16]
XL880	DMHJTR2	Breast cancer	2C60-2C65	Phase 2	[14]
Anti-VEGFR2 CD8 cell therapy	DM2910G	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[26]
Elpamotide	DM5FCO4	Biliary cancer	2E92.7	Phase 1/2	[27]
MK-2461	DM21WBH	Alzheimer disease	8A20	Phase 1/2	[28]
OTSGC-A24	DMN0ZQ5	Colorectal cancer	2B91.Z	Phase 1/2	[29]
A168	DMJW3F4	Gastric adenocarcinoma	2B72	Phase 1	[30]
Altiratinib	DMUJCBT	Solid tumour/cancer	2A00-2F9Z	Phase 1	[31]
CEP-11981	DMYDTJ6	Solid tumour/cancer	2A00-2F9Z	Phase 1	[12]
CYC116	DMUMHXT	Solid tumour/cancer	2A00-2F9Z	Phase 1	[32]
E-7050	DMDOCNW	Head and neck cancer	2D42	Phase 1	[33]
KRN633	DMODGJU	Glioma	2A00.0	Phase 1	[12]
OSI-930	DMF2CZ9	Solid tumour/cancer	2A00-2F9Z	Phase 1	[34]
Pegdinetanib	DM0E37K	Non-small-cell lung cancer	2C25.Y	Phase 1	[19]
PF-00337210	DM5PUO0	Solid tumour/cancer	2A00-2F9Z	Phase 1	[35]
PLX-4720	DMBK9AM	Cutaneous melanoma	2C30	Phase 1	[36]
TAK-593	DMNFZOT	Solid tumour/cancer	2A00-2F9Z	Phase 1	[37]
XL999	DMYS13R	Advanced malignancy	2A00-2F9Z	Phase 1	[38]

10 Patented Agent(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Antibodie derivative 10	DMGP5AR	Angiogenesis disorder	BE2Z	Patented	[39]
Antibodie derivative 6	DMUG6YT	N. A.	N. A.	Patented	[39]
Pyridine derivative 18	DMBZMYT	N. A.	N. A.	Patented	[40]
Pyrimidine derivative 12	DMMBFQH	N. A.	N. A.	Patented	[39]
Pyrimidine derivative 13	DMASGR1	N. A.	N. A.	Patented	[39]
Pyrimidine derivative 14	DM7B2XG	N. A.	N. A.	Patented	[39]
Pyrimidine derivative 4	DM8K6IS	N. A.	N. A.	Patented	[39]
Quinazoline derivative 15	DMD965S	N. A.	N. A.	Patented	[40]
Quinazoline derivative 16	DMQ704Z	N. A.	N. A.	Patented	[40]
Quinoline and quinazoline derivative 1	DMKDTO4	N. A.	N. A.	Patented	[39]

5 Discontinued Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Motesanib	DMZAL8C	Non-small-cell lung cancer	2C25.Y	Discontinued in Phase 3	[41]
SU-14813	DMNRW68	Breast cancer	2C60-2C65	Discontinued in Phase 2	[12]
IMC-1C11	DMQIXD2	Solid tumour/cancer	2A00-2F9Z	Discontinued in Phase 1	[42]
AG1295	DMT10C2	N. A.	N. A.	Terminated	[43]
CEP-5214	DMFRW0G	Solid tumour/cancer	2A00-2F9Z	Terminated	[44]

71 Investigative Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
(2-Methoxy-phenyl)-(5-phenyl-oxazol-2-yl)-amine	DMQWD75	Discovery agent	N.A.	Investigative	[45]
(3-Phenoxy-phenyl)-(5-phenyl-oxazol-2-yl)-amine	DMGYAP7	Discovery agent	N.A.	Investigative	[45]
(4-Phenoxy-phenyl)-quinazolin-4-yl-amine	DMFO8DR	Discovery agent	N.A.	Investigative	[46]
(5-Phenyl-oxazol-2-yl)-m-tolyl-amine	DM1R5SF	Discovery agent	N.A.	Investigative	[45]
2-(1H-indazol-3-yl)-1H-benzo[d]imidazole	DM0CSH8	Discovery agent	N.A.	Investigative	[47]
2-(5-Phenyl-oxazol-2-ylamino)-benzonitrile	DMX6QMT	Discovery agent	N.A.	Investigative	[45]
2-(p-toluidino)-4-phenylpyrimidine-5-carbonitrile	DM27YTF	Discovery agent	N.A.	Investigative	[48]
2-(pyrimidin-4-ylamino)thiazole-5-carbonitrile	DMET46L	Discovery agent	N.A.	Investigative	[49]
3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione	DMDO175	Discovery agent	N.A.	Investigative	[50]
3,4-diphenyl-1H-pyrrole-2,5-dione	DMPK6YT	Discovery agent	N.A.	Investigative	[50]
3,6-Di-pyridin-4-yl-pyrazolo[1,5-a]pyrimidine	DMNV0EZ	Discovery agent	N.A.	Investigative	[51]
3-((3-bromothiophen-2-yl)methylene)indolin-2-one	DME3079	Discovery agent	N.A.	Investigative	[52]
3-(1H-Indol-2-yl)-1H-quinolin-2-one	DMS3JCN	Discovery agent	N.A.	Investigative	[53]
3-(4-aminophenyl)thieno[3,2-c]pyridin-4-amine	DM30GV2	Discovery agent	N.A.	Investigative	[54]
3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione	DMGC7RY	Discovery agent	N.A.	Investigative	[50]
3-(5-Phenyl-oxazol-2-ylamino)-benzonitrile	DMPBLM2	Discovery agent	N.A.	Investigative	[45]
3-(5-Thiophen-3-yl-pyridin-3-yl)-1H-indole	DM9LVR5	Discovery agent	N.A.	Investigative	[55]
3-Benzimidazol-2-ylhydroquinolin-2-one	DMQXJA1	Discovery agent	N.A.	Investigative	[56]
3-methyl-1H-thieno[2,3-c]pyrazole-5-carboxamide	DMKOX0N	Discovery agent	N.A.	Investigative	[57]
3-phenyl-1,4-dihydroindeno[1,2-c]pyrazole	DMD0OZ8	Discovery agent	N.A.	Investigative	[58]
4-(4-aminophenyl)-1H-indazol-3yl-amine	DMK1IWD	Discovery agent	N.A.	Investigative	[59]
4-(4-m-Tolylamino-phthalazin-1-yl)-benzamide	DM3KCL1	Discovery agent	N.A.	Investigative	[60]
4-(4-p-Tolylamino-phthalazin-1-yl)-benzamide	DM6ESXB	Discovery agent	N.A.	Investigative	[60]
4-(5-Phenyl-oxazol-2-ylamino)-benzenesulfonamide	DM3N9O5	Discovery agent	N.A.	Investigative	[45]
4-(isoquinolin-5-yl)-N-m-tolylphthalazin-1-amine	DM8LODU	Discovery agent	N.A.	Investigative	[61]
4-(isoquinolin-5-yl)-N-o-tolylphthalazin-1-amine	DMS30HQ	Discovery agent	N.A.	Investigative	[61]
4-Chloro-N-(2-chloro-benzoyl)-benzenesulfonamide	DMVJ61A	Discovery agent	N.A.	Investigative	[62]
4-Chloro-N-(2-methyl-benzoyl)-benzenesulfonamide	DM6SI78	Discovery agent	N.A.	Investigative	[62]
4-Chloro-N-(3-chloro-benzoyl)-benzenesulfonamide	DMI3OR9	Discovery agent	N.A.	Investigative	[62]
4-Chloro-N-(4-chloro-benzoyl)-benzenesulfonamide	DMTDX2S	Discovery agent	N.A.	Investigative	[62]
4-Chloro-N-(4-nitro-benzoyl)-benzenesulfonamide	DMM0TL6	Discovery agent	N.A.	Investigative	[62]
4-phenyl-2-(phenylamino)pyrimidine-5-carbonitrile	DMONKDQ	Discovery agent	N.A.	Investigative	[48]
4-[3-Hydroxyanilino]-6,7-Dimethoxyquinazoline	DMTIA27	Discovery agent	N.A.	Investigative	[52]
5-(4-Methoxy-phenyl)-1-phenyl-1H-benzoimidazole	DMCMNKA	Discovery agent	N.A.	Investigative	[63]
6-(1H-Benzoimidazol-2-yl)-benzocyclohepten-7-one	DM5RX0K	Discovery agent	N.A.	Investigative	[53]
6-o-tolylquinazolin-2-amine	DM4TX9O	Discovery agent	N.A.	Investigative	[64]
8-methyl-4H,7H-indolo[6,5,4-cd]indol-5-one	DMA28OL	Discovery agent	N.A.	Investigative	[52]
AAL-993	DM35RFH	Discovery agent	N.A.	Investigative	[8]
AG-E-85378	DM83951	Discovery agent	N.A.	Investigative	[65]
AMG-429	DME04BH	Solid tumour/cancer	2A00-2F9Z	Investigative	[19]
AST-487	DME76KU	Discovery agent	N.A.	Investigative	[66]
BIBF-1202	DMDTLSP	Discovery agent	N.A.	Investigative	[67]
BMS-536924	DMXJB4N	Discovery agent	N.A.	Investigative	[68]
BMS-645737	DMBTMO9	Discovery agent	N.A.	Investigative	[69]
BX-795	DMRIMLJ	Discovery agent	N.A.	Investigative	[70]
BX-912	DMZA45C	Discovery agent	N.A.	Investigative	[70]
CB-676475	DMXON4L	Discovery agent	N.A.	Investigative	[71]
CEP-5104	DMV43GY	Discovery agent	N.A.	Investigative	[72]
EPI-0030	DM72DO1	Solid tumour/cancer	2A00-2F9Z	Investigative	[19]
IM-023911	DMZW0YO	Discovery agent	N.A.	Investigative	[60]
IM-094261	DMTFV65	Discovery agent	N.A.	Investigative	[60]
IM-094882	DMO18YN	Discovery agent	N.A.	Investigative	[61]
Indolin-2-one deriv. 4b	DMML9AY	Discovery agent	N.A.	Investigative	[73]
Isoindolinone Urea derivative	DMQC4HV	Discovery agent	N.A.	Investigative	[74]
JNJ-38158471	DM48Y9E	Angiogenesis disorder	BE2Z	Investigative	[19]
K-252a analogue	DMCZPH4	Discovery agent	N.A.	Investigative	[75]
Ki-20227	DM9M3VC	Discovery agent	N.A.	Investigative	[76]
L000021649	DMYWD6C	Discovery agent	N.A.	Investigative	[51]
N-(2,4-Dichloro-benzoyl)-benzenesulfonamide	DMHI4Y6	Discovery agent	N.A.	Investigative	[62]
N-(3-Bromo-benzoyl)-4-chloro-benzenesulfonamide	DMOQ08F	Discovery agent	N.A.	Investigative	[62]
Phenyl-(5-phenyl-oxazol-2-yl)-amine	DMR2B4O	Discovery agent	N.A.	Investigative	[45]
PMID22765894C8h	DMH5RFU	Discovery agent	N.A.	Investigative	[77]
PMID23639540C13a	DMLXOAQ	Discovery agent	N.A.	Investigative	[78]
PP121	DMU8KTO	Discovery agent	N.A.	Investigative	[79]
Pyrazolo[1,5-a]pyrimidine 3G	DMUB0EJ	Discovery agent	N.A.	Investigative	[51]
R-84	DM1MIRJ	Solid tumour/cancer	2A00-2F9Z	Investigative	[19]
Ro-4396686	DM5DMCH	Discovery agent	N.A.	Investigative	[80]
SU-11652	DMGQXN7	Discovery agent	N.A.	Investigative	[81]
TG-100435	DMIR3X2	Discovery agent	N.A.	Investigative	[82]
VEGF receptor 2 kinase inhibitor I	DMWXCYA	Discovery agent	N.A.	Investigative	[83]
[3-(5-Phenyl-oxazol-2-ylamino)-phenyl]-methanol	DMD0LCU	Discovery agent	N.A.	Investigative	[45]

References

• [1] Nat Rev Drug Discov. 2013 Feb;12(2):87-90.
• [2] Clinical pipeline report, company report or official report of Exelixis (2011).
• [3] Discovery of fruquintinib, a potent and highly selective small molecule inhibitor of VEGFR 1, 2, 3 tyrosine kinases for cancer therapy. Cancer Biol Ther. 2014;15(12):1635-45.
• [4] Emerging drugs for ovarian cancer. Expert Opin Emerg Drugs. 2008 Sep;13(3):523-36.
• [5] Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
• [6] 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
• [7] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [8] Anthranilic acid amides: a novel class of antiangiogenic VEGF receptor kinase inhibitors. J Med Chem. 2002 Dec 19;45(26):5687-93.
• [9] Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling.Mol Cancer Ther.2008 Oct;7(10):3129-40.
• [10] 2006 drug approvals: finding the niche. Nat Rev Drug Discov. 2007 Feb;6(2):99-101.
• [11] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services
• [12] A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
• [13] YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase with potent activity in vitro and in vivo. Cancer Sci. 2011 Jul;102(7):1374-80.
• [14] Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
• [15] E-3810 is a potent dual inhibitor of VEGFR and FGFR that exerts antitumor activity in multiple preclinical models. Cancer Res. 2011 Feb 15;71(4):1396-405.
• [16] Dual irreversible kinase inhibitors: quinazoline-based inhibitors incorporating two independent reactive centers with each targeting different cyst... Bioorg Med Chem. 2007 Jun 1;15(11):3635-48.
• [17] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [18] Clinical pipeline report, company report or official report of Hutchison Medi Pharma.
• [19] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1813).
• [20] Phase I evaluation of CDP791, a PEGylated di-Fab' conjugate that binds vascular endothelial growth factor receptor 2. Clin Cancer Res. 2007 Dec 1;13(23):7113-8.
• [21] Preclinical pharmacokinetics and in vitro metabolism of BMS-690514, a potent inhibitor of EGFR and VEGFR2. J Pharm Sci. 2010 Aug;99(8):3579-93.
• [22] Delphinidin, a dietary anthocyanidin, inhibits vascular endothelial growth factor receptor-2 phosphorylation. Carcinogenesis. 2006 May;27(5):989-96.
• [23] Metabolism and bioactivation of famitinib, a novel inhibitor of receptor tyrosine kinase, in cancer patients. Br J Pharmacol. 2013 Apr;168(7):1687-706.
• [24] Clinical pipeline report, company report or official report of Helix BioPharma.
• [25] RAF265, a dual BRAF and VEGFR2 inhibitor, prevents osteoclast formation and resorption. Therapeutic implications. Invest New Drugs. 2013 Feb;31(1):200-5.
• [26] Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy. Proc Natl Acad Sci U S A. 2012 Oct 23;109(43):17561-6.
• [27] Clinical phase I study of elpamotide, a peptide vaccine for vascular endothelial growth factor receptor 2, in patients with advanced solid tumors. Cancer Sci. 2012 Dec;103(12):2135-8.
• [28] MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor. Cancer Res. 2010 Feb 15;70(4):1524-33.
• [29] J Clin Oncol 33, 2015 (suppl 3; abstr 65).
• [30] Clinical pipeline report, company report or official report of Klus Pharma
• [31] Clinical pipeline report, company report or official report of Deciphera Pharmaceuticals.
• [32] Clinical pipeline report, company report or official report of Cyclacel.
• [33] E7050: a dual c-Met and VEGFR-2 tyrosine kinase inhibitor promotes tumor regression and prolongs survival in mouse xenograft models. Cancer Sci. 2010 Jan;101(1):210-5.
• [34] OSI-930 analogues as novel reversal agents for ABCG2-mediated multidrug resistance. Biochem Pharmacol. 2012 Sep 15;84(6):766-74.
• [35] Inhibition of VEGFR-2 Reverses Type 1 Diabetes in NOD Mice by Abrogating Insulitis and Restoring Islet Function. Diabetes. 2013 August; 62(8): 2870-2878.
• [36] In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res. 2003 Jan;9(1):327-37.
• [37] Biochemical characterization of TAK-593, a novel VEGFR/PDGFR inhibitor with a two-step slow binding mechanism. Biochemistry. 2011 Feb 8;50(5):738-51.
• [38] Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2007 Mar;29(2):153-73.
• [39] VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004.
• [40] RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99.
• [41] Clinical pipeline report, company report or official report of Amgen (2009).
• [42] Technology evaluation: IMC-1C11, ImClone Systems. Curr Opin Mol Ther. 2001 Aug;3(4):418-24.
• [43] Design, synthesis, and X-ray crystal structures of 2,4-diaminofuro[2,3-d]pyrimidines as multireceptor tyrosine kinase and dihydrofolate reductase i... Bioorg Med Chem. 2009 Oct 15;17(20):7324-36.
• [44] Neuropilin-2 interacts with VEGFR-2 and VEGFR-3 and promotes human endothelial cell survival and migration. Blood. 2006 Aug 15;108(4):1243-50.
• [45] Discovery and evaluation of 2-anilino-5-aryloxazoles as a novel class of VEGFR2 kinase inhibitors. J Med Chem. 2005 Mar 10;48(5):1610-9.
• [46] Pyrrolo[2,3-d]pyrimidines containing an extended 5-substituent as potent and selective inhibitors of lck I. Bioorg Med Chem Lett. 2000 Oct 2;10(19):2167-70.
• [47] Design and structure-activity relationship of 3-benzimidazol-2-yl-1H-indazoles as inhibitors of receptor tyrosine kinases. Bioorg Med Chem Lett. 2006 Jul 1;16(13):3595-9.
• [48] 4-Aryl-5-cyano-2-aminopyrimidines as VEGF-R2 inhibitors: synthesis and biological evaluation. Bioorg Med Chem Lett. 2007 Jun 15;17(12):3266-70.
• [49] Potent 2-[(pyrimidin-4-yl)amine}-1,3-thiazole-5-carbonitrile-based inhibitors of VEGFR-2 (KDR) kinase. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1146-50.
• [50] Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors. J Med Chem. 2006 Feb 23;49(4):1271-81.
• [51] Optimization of a pyrazolo[1,5-a]pyrimidine class of KDR kinase inhibitors: improvements in physical properties enhance cellular activity and pharm... Bioorg Med Chem Lett. 2002 Dec 16;12(24):3537-41.
• [52] Pharmacophore modeling and in silico screening for new KDR kinase inhibitors. Bioorg Med Chem Lett. 2007 Apr 15;17(8):2126-33.
• [53] Optimization of the indolyl quinolinone class of KDR (VEGFR-2) kinase inhibitors: effects of 5-amido- and 5-sulphonamido-indolyl groups on pharmaco... Bioorg Med Chem Lett. 2004 Jan 19;14(2):351-5.
• [54] Thienopyridine urea inhibitors of KDR kinase. Bioorg Med Chem Lett. 2007 Mar 1;17(5):1246-9.
• [55] Discovery and evaluation of 3-(5-thien-3-ylpyridin-3-yl)-1H-indoles as a novel class of KDR kinase inhibitors. Bioorg Med Chem Lett. 2003 Sep 15;13(18):2973-6.
• [56] Design, structure-activity relationships and in vivo characterization of 4-amino-3-benzimidazol-2-ylhydroquinolin-2-ones: a novel class of receptor... J Med Chem. 2009 Jan 22;52(2):278-92.
• [57] Scaffold oriented synthesis. Part 1: Design, preparation, and biological evaluation of thienopyrazoles as kinase inhibitors. Bioorg Med Chem Lett. 2006 Jan 1;16(1):96-9.
• [58] Hit-to-lead optimization of 1,4-dihydroindeno[1,2-c]pyrazoles as a novel class of KDR kinase inhibitors. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4371-5.
• [59] Discovery of N-(4-(3-amino-1H-indazol-4-yl)phenyl)-N'-(2-fluoro-5-methylphenyl)urea (ABT-869), a 3-aminoindazole-based orally active multitargeted ... J Med Chem. 2007 Apr 5;50(7):1584-97.
• [60] Arylphthalazines: identification of a new phthalazine chemotype as inhibitors of VEGFR kinase. Bioorg Med Chem Lett. 2005 Nov 1;15(21):4696-8.
• [61] Arylphthalazines. Part 2: 1-(Isoquinolin-5-yl)-4-arylamino phthalazines as potent inhibitors of VEGF receptors I and II. Bioorg Med Chem Lett. 2006 Mar 15;16(6):1579-81.
• [62] Acyl sulfonamide anti-proliferatives: benzene substituent structure-activity relationships for a novel class of antitumor agents. J Med Chem. 2004 Oct 21;47(22):5367-80.
• [63] Design and synthesis of 1,5-diarylbenzimidazoles as inhibitors of the VEGF-receptor KDR. Bioorg Med Chem Lett. 2003 Aug 4;13(15):2485-8.
• [64] Discovery of aminoquinazolines as potent, orally bioavailable inhibitors of Lck: synthesis, SAR, and in vivo anti-inflammatory activity. J Med Chem. 2006 Sep 21;49(19):5671-86.
• [65] Discovery of N-phenyl nicotinamides as potent inhibitors of Kdr. Bioorg Med Chem Lett. 2007 Nov 1;17(21):6003-8.
• [66] The RET kinase inhibitor NVP-AST487 blocks growth and calcitonin gene expression through distinct mechanisms in medullary thyroid cancer cells. Cancer Res. 2007 Jul 15;67(14):6956-64.
• [67] Comprehensive analysis of kinase inhibitor selectivity. Nat Biotechnol. 2011 Oct 30;29(11):1046-51.
• [68] Discovery of a (1H-benzoimidazol-2-yl)-1H-pyridin-2-one (BMS-536924) inhibitor of insulin-like growth factor I receptor kinase with in vivo antitum... J Med Chem. 2005 Sep 8;48(18):5639-43.
• [69] Discovery and preclinical studies of 5-isopropyl-6-(5-methyl-1,3,4-oxadiazol-2-yl)-N-(2-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]t... Bioorg Med Chem Lett. 2008 May 1;18(9):2985-9.
• [70] Novel small molecule inhibitors of 3-phosphoinositide-dependent kinase-1. J Biol Chem. 2005 May 20;280(20):19867-74.
• [71] Synthesis of a novel biotin-tagged photoaffinity probe for VEGF receptor tyrosine kinases. Bioorg Med Chem Lett. 2006 Jan 1;16(1):129-33.
• [72] Mixed-lineage kinase 1 and mixed-lineage kinase 3 subtype-selective dihydronaphthyl[3,4-a]pyrrolo[3,4-c]carbazole-5-ones: optimization, mixed-linea... J Med Chem. 2008 Sep 25;51(18):5680-9.
• [73] Identification of substituted 3-[(4,5,6, 7-tetrahydro-1H-indol-2-yl)methylene]-1,3-dihydroindol-2-ones as growth factor receptor inhibitors for VEGF-R2 (Flk-1/KDR), FGF-R1, and PDGF-Rbeta tyrosine kinases. J Med Chem. 2000 Jul 13;43(14):2655-63.
• [74] Isoindolinone ureas: a novel class of KDR kinase inhibitors. Bioorg Med Chem Lett. 2004 Sep 6;14(17):4505-9.
• [75] Synthesis, modeling, and in vitro activity of (3'S)-epi-K-252a analogues. Elucidating the stereochemical requirements of the 3'-sugar alcohol on tr... J Med Chem. 2005 Jun 2;48(11):3776-83.
• [76] A c-fms tyrosine kinase inhibitor, Ki20227, suppresses osteoclast differentiation and osteolytic bone destruction in a bone metastasis model. Mol Cancer Ther. 2006 Nov;5(11):2634-43.
• [77] The design, synthesis, and biological evaluation of potent receptor tyrosine kinase inhibitors. Bioorg Med Chem Lett. 2012 Aug 1;22(15):4979-85.
• [78] Synthesis and structure-activity relationships of a novel and selective bone morphogenetic protein receptor (BMP) inhibitor derived from the pyrazolo[1.5-a]pyrimidine scaffold of dorsomorphin: the discovery of ML347 as an ALK2 versus ALK3 selective MLPCN probe. Bioorg Med Chem Lett. 2013 Jun 1;23(11):3248-52.
• [79] Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases. Nat Chem Biol. 2008 Nov;4(11):691-9.
• [80] Biological evaluation of a multi-targeted small molecule inhibitor of tumor-induced angiogenesis. Bioorg Med Chem Lett. 2006 Apr 1;16(7):1950-3.
• [81] Discovery of 5-[5-fluoro-2-oxo-1,2- dihydroindol-(3Z)-ylidenemethyl]-2,4- dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel... J Med Chem. 2003 Mar 27;46(7):1116-9.
• [82] Discovery of [7-(2,6-dichlorophenyl)-5-methylbenzo [1,2,4]triazin-3-yl]-[4-(2-pyrrolidin-1-ylethoxy)phenyl]amine--a potent, orally active Src kinas... Bioorg Med Chem Lett. 2007 Feb 1;17(3):602-8.
• [83] Synthesis and biological evaluations of 3-substituted indolin-2-ones: a novel class of tyrosine kinase inhibitors that exhibit selectivity toward particular receptor tyrosine kinases. J Med Chem. 1998 Jul 2;41(14):2588-603.